Biofrontera announces preliminary revenue for Q1 2021
April 08, 2021 10:30 ET
|
Biofrontera AG
Leverkusen, Germany, April 08, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported...
Biofrontera announces conference call to be held on April 13, 2021 to discuss fiscal year 2020 financial results
March 31, 2021 10:12 ET
|
Biofrontera AG
Leverkusen, Germany, March 31, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be releasing...
Biofrontera submits application for FDA approval of new BF-RhodoLED® XL lamp
March 31, 2021 03:40 ET
|
Biofrontera AG
Leverkusen, Germany, March 31, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today announced the...
Biofrontera AG announces the closing of the capital raise with gross proceeds of EUR 24.7 million
February 26, 2021 09:20 ET
|
Biofrontera AG
Leverkusen, Germany, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (“Biofrontera” or the “Company”), an international biopharmaceutical company,...
Biofrontera submits study report of pharmacokinetics study to FDA
February 24, 2021 08:30 ET
|
Biofrontera AG
Leverkusen, Germany, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announces the...
Biofrontera AG Announces Pricing of US$8.9 Million Firm Commitment Public Offering of American Depositary Shares
February 23, 2021 19:54 ET
|
Biofrontera AG
NOT FOR DISTRIBUTION OUTSIDE THE UNITED STATES Leverkusen, Germany, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (“Biofrontera” or the...
Biofrontera AG: Ludwig Lutter appointed new Chief Financial Officer effective March 1, 2021
February 02, 2021 10:35 ET
|
Biofrontera AG
Leverkusen, Germany, Feb. 02, 2021 (GLOBE NEWSWIRE) -- The Supervisory Board of Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical...
Biofrontera announces preliminary revenue figures for the full year 2020
January 08, 2021 09:35 ET
|
Biofrontera AG
Leverkusen, Germany, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported...
Cologne Higher Regional Court grants approval of capital increase
January 07, 2021 11:45 ET
|
Biofrontera AG
Leverkusen, Germany, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announces that the...
Biofrontera enters into a license and supply agreement with Galenica AB for the marketing of Ameluz® in Scandinavia
December 07, 2020 09:10 ET
|
Biofrontera AG
Leverkusen, Germany, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Biofrontera Pharma GmbH, a wholly owned subsidiary of Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F), and Galenica AB, Malmö,...